

Introduction

Center for Future Technologies in Cancer Care

Catherine Klapperich, Ph.D.

Director


Boston University

9 June 2016



How New Cancer Treatments Are Shaping Lives

By THE NEW YORK TIMES MAGAZINE MAY 15, 2016



Linda McCulloch

Immunotherapy,
Brain Cancer
Remission



William Burhans

Targeted Therapy,
Remission from
BRCA-positive
prostate cancer



Andrew Levy

Immunotherapy,
Leukemia Remission

Precision Medicine

“Precision medicine is not the future of cancer care, it is the present. This study reinforces that the more we personalize treatment to the patient and the tumor, the better the outcomes – even in the earliest phases of research,” said Don S. Dizon, MD, FACP.

- Who will benefit most from these new therapies?
- How can we improve **healthcare delivery** to impact the most patients?
- Will these new therapies and their cost worsen **health disparities**?

Point of Care and the New Cancer Care

- In order to reduce costs, it will be necessary to have the following information accessible to clinicians and their patients
 - **Inexpensive sequencing data** of primary and metastatic tumors.
 - **Tumors monitored molecularly** throughout the course of treatment.
 - **Assessment of therapy earlier** in treatment. Early detection of new acquired mutations that might enable resistance.
 - Management of these tests throughout the course of care.
 - **High touch patient management** with fewer office visits.
 - Putting **quality of life** issues front and center.

Disparities in Cancer Care

Documented cancer health disparities include:

- a higher incidence of a particularly aggressive form of breast cancer (the triple-negative subtype) among African American women than women of other racial/ethnic groups
- substantially higher rates of prostate cancer incidence and death among African American men than men of other racial/ethnic groups
- higher rates of kidney cancer among American Indian and Alaska Natives than other racial/ethnic groups
- higher rates of liver cancer among Asian and Pacific Islanders than other racial/ethnic groups
- higher rates of cervical cancer incidence and death among Hispanic and African American women than women of other racial/ethnic groups

Global Disparities in Cancer Care

Areas to address global health disparities in cancer care include:


- Tobacco Control
- Obesity, Diet and Exercise
- Vaccines
- Prevention, Early Detection, Treatment
- Palliative Care

Means to address these disparities:

- Mobile Health Applications
- EMRs
- Point of Care Diagnosis and Risk Stratification
- Treatment Monitoring
- Quality of Life Technologies




Cancer detection and treatment is evolving rapidly, and the CFTCC strives to keep test developers on top of the change.




CFTCC is focused on the identification, prototyping and early clinical assessment of innovative point of care technologies for the treatment, screening, diagnosis and monitoring of cancers.

We aid investigators in the assessment of early stage technologies in terms of clinical needs, market demands and setting appropriateness.


The Center has as strong emphasis on prototyping activities.



Summary of Prototype Projects to Date



Progress of Projects Through the Center



Alpha Prototyping Core

Equipment


- Microarray
- Laser Cutter
- Wax printer
- Cutter Plotter
- Real-Time PCR System
- 3-D Printer
- Desktop mill
- Laminator
- Stereomicroscope



Stratasys uPrint SE



Nikon SMZ18



Other facilities


- Class 1000 cleanroom
- Precision Measurement Laboratory
- EPIC machine shop
- BSL 2 Lab Access

A New Wearable Optical Probe for Chemotherapy Monitoring.

PI: Darren Roblyer, Boston University, Biomedical Engineering

Co-PI: Alexis Sauer-Budge, Fraunhofer CFI

Motivation



Problem:
It can take months to determine chemosensitivity with current methods

Barrier:
Adaptive Therapy Requires Better Feedback




Our Solution:
Wearable Diffuse Optical Imaging



The Wearable probe will be placed on the skin of a breast cancer patient over a known tumor location. Continuous measurements will be taken during chemotherapy infusions.

The Wearable probe is designed to conform to breast tissue.

It measures tumor metabolism during chemotherapy for early response prediction.




- Optical Spectroscopy for Improved PCP Screening of Colorectal Cancer
PI: Irving Bigio, Ph.D. (JHU)
Co-PI: Sarah Singh, M.D. (BUSM, Boston VA Hospital)
- Improving Hepatocellular Carcinoma Patient Outcomes with a Novel Multiplexed Point-of-Care Biomarker Measurement System
PI: Daniel Lacer, Ph.D. (wave80 Biosciences, Inc.)
Co-PI: Catherine Klappert, PhD (SI)
- miRNA Gel Pads for the Point of Care Detection of Lung Cancer Biomarkers in Serum
PI: Patrick Doyle, Ph.D. (MIT)
Co-PI: Avram Spira, M.D. (BUSM)
- Non-Enzymatic DNA Amplification Circuit for Cancer Biomarker Testing (melanoma)
PI: Andrew Elington, PhD (UF-Austin)
Co-PI: Rhonda Alani, M.D. (BUSM)
- My LifeCloud: A Mobile Based System Aimed at Empowering Patients Who are at Risk for Colorectal Cancer
PI: Kelly Brittain, Ph.D. (Michigan State University)
Co-PI: Dr. Christine Cassandras (JHU, Systems Engineering), Mr. Jose Gomez-Munoz (MIT)
- Personal Health Network Technology-Chemotherapy Monitoring
PI: Jill Joseph, University of California, Davis
- A New Wearable Technology-Chemotherapy Monitoring
PI: Damaris Roblyer, Boston University, COE
- Smartphone App for Chronic Pain Care-Cancer Patient
PI: Robert Jamison, Brigham and Women's Hospital
- POC Tumor Marker Detection-Ovarian Tumors
PI: Justin Bacia, University of New Mexico
- A Nanopore-Nanofiber Mesh Biosensor
PI: Mark Gimzewski, Boston University, COE
- Topical Treatment of Oral Cancer
PI: Manjeh Goldberg, Prive Technologies, Inc.
- Evaluation of mHealth Counseling for Lifestyle Behaviors Among Breast Cancer Survivors
PI: Lisa Quinlan, Boston Medical Center School of Medicine

- Development of a Completely Passive Hemo Monitoring System for Early Detection of Cardiovascular Complication of Cancer and its Treatments
Kevin King, Ph.D., Brigham and Women's Hospital
- A New Point-of-Care Diffuse Optical Imaging System for Home and Clinical Monitoring of Chemotherapy Response in Breast Cancer Patients
Damaris Roblyer, Ph.D., Boston University
- Development of Phosphorescent Near-Infrared Fluorophores for Bone Tumor Targeting
Hoon Hyun, Ph.D., Beth Israel Deaconess Medical Center, Harvard Medical School

- KEY**
- S** Students
 - Sc** Scientists
 - C** Clinicians
 - E** Engineers
 - A** Academics
 - I** Industry

- Manage funding opportunities
- Develop and hosting training sessions
- Discuss and seek future opportunities for improved cancer care

- Provide prototyping equipment and materials
- Consultation on alpha prototypes
- Device development



Center Outreach

Facebook
CFTCC




Workshops and Training

Photonics Center, Boston
Fraunhofer CMI
Alpha Prototyping Core



Twitter
@CFTCC_NIBIB
@DrKlapperich



Web Based Resources and Archives

www.bu.edu/CFTCC
www.POCTRN.org

